Hai T. Tran, PharmD
Patients with advanced non–small cell lung cancer (NSCLC) and actionable mutations had similar progression-free survival (PFS) whether treatment guidance came from tissue or circulating tumor (ct)DNA analysis using the Guardant360 assay, a matched retrospective comparison showed.
The comparison of targetable mutations identified by ctDNA and tissue in 122 matched cases showed strong agreement between the 2 testing techniques. The overall diagnostic accuracy was 99.6% and was 100% for 8 of 11 types of targetable mutations identified. Sensitivity was 99.2%, specificity 99.7%, PPV 96.7%, and NPV 99.9%.
Tran H, Lam V, Vasquez M, et al. Outcomes in advanced NSCLC patients treated with 1st line EGFR-TKI based on mutation detection from tissue or cfDNA-based genomic sequencing. Presented at: IASLC 20th World Conference on Lung Cancer; September 7-10, 2019; Barcelona, Spain. Abstract P1.01-98.
... to read the full story